Search

Your search keyword '"da Silva Duarte, Alberto Jos��"' showing total 13 results
Start Over Author "da Silva Duarte, Alberto Jos��"
13 results on '"da Silva Duarte, Alberto Jos��"'

1. Additional file 2 of Immunogenicity of personalized dendritic-cell therapy in HIV-1 infected individuals under suppressive antiretroviral treatment: interim analysis from a phase II clinical trial

Author

de Almeida Baptista, Marcella Vass��o, da Silva, La��s Teodoro, Samer, Sadia, Oshiro, Telma Miyuki, Shytaj, Iart Luca, Giron, Leila B., Pena, Nathalia Mantovani, Cruz, Nicolly, Gosuen, Gisele Cristina, Ferreira, Paulo Roberto Abr��o, Cunha-Neto, Ed��cio, Galinskas, Juliana, Dias, Danilo, Sucupira, Maria Cecilia Araripe, de Almeida-Neto, Cesar, Salom��o, Reinaldo, da Silva Duarte, Alberto Jos��, Janini, Lu��s M��rio, Hunter, James R., Savarino, Andrea, Juliano, Maria Aparecida, and Diaz, Ricardo Sobhie

Abstract

Additional file 2: Fig. S2. Representative example of the viability of MDDCs under different maturation protocols and conditions. MDDCs were isolated from PBMCs and induced to maturation according to two protocols based on IL-4 and IFN-�� as depicted in Additional file 1: Fig. S1. Maturation of MDDCs was performed starting from either freshly collected PBMCs (red bars) or PBMCs frozen in liquid nitrogen upon collection and thawed after 2 weeks. Viability was assessed by flow cytometry using a LIVE/DEAD stain. Data were normalized over the fresh-cell condition.

Published
2022
Full Text
View/download PDF

2. Additional file 11 of Immunogenicity of personalized dendritic-cell therapy in HIV-1 infected individuals under suppressive antiretroviral treatment: interim analysis from a phase II clinical trial

Author

de Almeida Baptista, Marcella Vass��o, da Silva, La��s Teodoro, Samer, Sadia, Oshiro, Telma Miyuki, Shytaj, Iart Luca, Giron, Leila B., Pena, Nathalia Mantovani, Cruz, Nicolly, Gosuen, Gisele Cristina, Ferreira, Paulo Roberto Abr��o, Cunha-Neto, Ed��cio, Galinskas, Juliana, Dias, Danilo, Sucupira, Maria Cecilia Araripe, de Almeida-Neto, Cesar, Salom��o, Reinaldo, da Silva Duarte, Alberto Jos��, Janini, Lu��s M��rio, Hunter, James R., Savarino, Andrea, Juliano, Maria Aparecida, and Diaz, Ricardo Sobhie

Abstract

Additional file 11: Table S1. List of peptides used for pulsing MDDCs of each individual. Enneamers (9 mers) were designed according to their predicted immunogenicity in a given individual, as described in the main text. Peptides were then used to pulse MDDCs before their reinfusion in MDDCT recipients according to the workflow depicted in Additional file 1: Fig. S1. Note that some autologous peptides are common to more than one patient.

Published
2022
Full Text
View/download PDF

3. Additional file 7 of Immunogenicity of personalized dendritic-cell therapy in HIV-1 infected individuals under suppressive antiretroviral treatment: interim analysis from a phase II clinical trial

Author

de Almeida Baptista, Marcella Vass��o, da Silva, La��s Teodoro, Samer, Sadia, Oshiro, Telma Miyuki, Shytaj, Iart Luca, Giron, Leila B., Pena, Nathalia Mantovani, Cruz, Nicolly, Gosuen, Gisele Cristina, Ferreira, Paulo Roberto Abr��o, Cunha-Neto, Ed��cio, Galinskas, Juliana, Dias, Danilo, Sucupira, Maria Cecilia Araripe, de Almeida-Neto, Cesar, Salom��o, Reinaldo, da Silva Duarte, Alberto Jos��, Janini, Lu��s M��rio, Hunter, James R., Savarino, Andrea, Juliano, Maria Aparecida, and Diaz, Ricardo Sobhie

Abstract

Additional file 7: Fig. S7. Cytokine expression in unstimulated CD4+ and CD8+ T-lymphocytes following MDDC MDDCT. Data were obtained as described in Fig. 3.

Published
2022
Full Text
View/download PDF

4. Additional file 6 of Immunogenicity of personalized dendritic-cell therapy in HIV-1 infected individuals under suppressive antiretroviral treatment: interim analysis from a phase II clinical trial

Author

de Almeida Baptista, Marcella Vass��o, da Silva, La��s Teodoro, Samer, Sadia, Oshiro, Telma Miyuki, Shytaj, Iart Luca, Giron, Leila B., Pena, Nathalia Mantovani, Cruz, Nicolly, Gosuen, Gisele Cristina, Ferreira, Paulo Roberto Abr��o, Cunha-Neto, Ed��cio, Galinskas, Juliana, Dias, Danilo, Sucupira, Maria Cecilia Araripe, de Almeida-Neto, Cesar, Salom��o, Reinaldo, da Silva Duarte, Alberto Jos��, Janini, Lu��s M��rio, Hunter, James R., Savarino, Andrea, Juliano, Maria Aparecida, and Diaz, Ricardo Sobhie

Abstract

Additional file 6: Fig. S6. Cytokine expression in SEB/brefeldin-stimulated CD4+ and CD8+ T-lymphocytes following MDDC MDDCT. Data were obtained as described in Fig. 3.

Published
2022
Full Text
View/download PDF

5. Additional file 3 of Immunogenicity of personalized dendritic-cell therapy in HIV-1 infected individuals under suppressive antiretroviral treatment: interim analysis from a phase II clinical trial

Author

de Almeida Baptista, Marcella Vass��o, da Silva, La��s Teodoro, Samer, Sadia, Oshiro, Telma Miyuki, Shytaj, Iart Luca, Giron, Leila B., Pena, Nathalia Mantovani, Cruz, Nicolly, Gosuen, Gisele Cristina, Ferreira, Paulo Roberto Abr��o, Cunha-Neto, Ed��cio, Galinskas, Juliana, Dias, Danilo, Sucupira, Maria Cecilia Araripe, de Almeida-Neto, Cesar, Salom��o, Reinaldo, da Silva Duarte, Alberto Jos��, Janini, Lu��s M��rio, Hunter, James R., Savarino, Andrea, Juliano, Maria Aparecida, and Diaz, Ricardo Sobhie

Subjects
hemic and immune systems
Abstract

Additional file 3: Fig. S3. Representative example of the maturation profile of MDDCs subjected to alternative differentiation and freezing protocols. MDDCs were isolated from PBMCs and induced to maturation according to two protocols based on IL-4 and IFN-�� as depicted in Additional file 1: Fig. S1. Maturation/activation markers CD80 and HLA-DR were analyzed by flow cytometry in cells isolated from fresh PBMCs or from PBMCs thawed after freezing using FBS or a specific freezing medium (as described in the Methods section).

Published
2022
Full Text
View/download PDF

6. Additional file 5 of Immunogenicity of personalized dendritic-cell therapy in HIV-1 infected individuals under suppressive antiretroviral treatment: interim analysis from a phase II clinical trial

Author

de Almeida Baptista, Marcella Vass��o, da Silva, La��s Teodoro, Samer, Sadia, Oshiro, Telma Miyuki, Shytaj, Iart Luca, Giron, Leila B., Pena, Nathalia Mantovani, Cruz, Nicolly, Gosuen, Gisele Cristina, Ferreira, Paulo Roberto Abr��o, Cunha-Neto, Ed��cio, Galinskas, Juliana, Dias, Danilo, Sucupira, Maria Cecilia Araripe, de Almeida-Neto, Cesar, Salom��o, Reinaldo, da Silva Duarte, Alberto Jos��, Janini, Lu��s M��rio, Hunter, James R., Savarino, Andrea, Juliano, Maria Aparecida, and Diaz, Ricardo Sobhie

Abstract

Additional file 5: Fig. S5. Gating strategy employed to analyze cytokine production in T-lymphocytes. Panels A, B. Cytokine production was determined in cells left unstimulated (A) or stimulated ex-vivo with the cell therapy peptides (B).

Published
2022
Full Text
View/download PDF

7. Additional file 1 of Age-associated phenotypic imbalance in TCD4 and TCD8 cell subsets: comparison between healthy aged, smokers, COPD patients and young adults

Author

Fernandes, Juliana Ruiz, Pinto, Thalyta Nery Carvalho, Arruda, Li�� Barbara, da Silva, Cibele Cristine Berto Marques, de Carvalho, Celso Ricardo Fernandes, Pinto, Regina Maria Carvalho, da Silva Duarte, Alberto Jos��, and Benard, Gil

Abstract

Additional file 1: Supplementary Table 1. Characteristics of the monoclonal antibodies used for immunophenotyping.

Published
2022
Full Text
View/download PDF

8. Additional file 2 of Age-associated phenotypic imbalance in TCD4 and TCD8 cell subsets: comparison between healthy aged, smokers, COPD patients and young adults

Author

Fernandes, Juliana Ruiz, Pinto, Thalyta Nery Carvalho, Arruda, Li�� Barbara, da Silva, Cibele Cristine Berto Marques, de Carvalho, Celso Ricardo Fernandes, Pinto, Regina Maria Carvalho, da Silva Duarte, Alberto Jos��, and Benard, Gil

Abstract

Additional file 2: Supplementary Table 2. Distribution (%) of comorbidities presented by the three aged groups. Main gastrointestinal disorders: gastritis, gastric ulcer, gastroenteritis, intolerance to lactose and dyspepsia. Cardiovascular diseases: arrhythmias, coronary artery disease, deep vein thrombosis, heart attack and strokes. Data are show as percentages, and Fisher test was used to compare the groups.

Published
2022
Full Text
View/download PDF

9. Additional file 4 of Immunogenicity of personalized dendritic-cell therapy in HIV-1 infected individuals under suppressive antiretroviral treatment: interim analysis from a phase II clinical trial

Author

de Almeida Baptista, Marcella Vass��o, da Silva, La��s Teodoro, Samer, Sadia, Oshiro, Telma Miyuki, Shytaj, Iart Luca, Giron, Leila B., Pena, Nathalia Mantovani, Cruz, Nicolly, Gosuen, Gisele Cristina, Ferreira, Paulo Roberto Abr��o, Cunha-Neto, Ed��cio, Galinskas, Juliana, Dias, Danilo, Sucupira, Maria Cecilia Araripe, de Almeida-Neto, Cesar, Salom��o, Reinaldo, da Silva Duarte, Alberto Jos��, Janini, Lu��s M��rio, Hunter, James R., Savarino, Andrea, Juliano, Maria Aparecida, and Diaz, Ricardo Sobhie

Abstract

Additional file 4: Fig. S4. Gating strategy employed to analyze maturation markers of MDDCs

Published
2022
Full Text
View/download PDF

10. Additional file 9 of Immunogenicity of personalized dendritic-cell therapy in HIV-1 infected individuals under suppressive antiretroviral treatment: interim analysis from a phase II clinical trial

Author

de Almeida Baptista, Marcella Vass��o, da Silva, La��s Teodoro, Samer, Sadia, Oshiro, Telma Miyuki, Shytaj, Iart Luca, Giron, Leila B., Pena, Nathalia Mantovani, Cruz, Nicolly, Gosuen, Gisele Cristina, Ferreira, Paulo Roberto Abr��o, Cunha-Neto, Ed��cio, Galinskas, Juliana, Dias, Danilo, Sucupira, Maria Cecilia Araripe, de Almeida-Neto, Cesar, Salom��o, Reinaldo, da Silva Duarte, Alberto Jos��, Janini, Lu��s M��rio, Hunter, James R., Savarino, Andrea, Juliano, Maria Aparecida, and Diaz, Ricardo Sobhie

Abstract

Additional file 9: Fig. S9. Impact of MDDCT on the level of IFN- �� in plasma. The Fig. shows the level of IFN-�� in individuals receiving the personalized dendritic-cell therapy (DCT), alone (G5, in black) or following the conditioning regimen consisting of auranofin + nicotinamide (G6, in blue). IFN-gamma was measured by ELISA testing, and data were analyzed by two-way ANOVA. The P-value reported refers to the interaction between time and the previous conditioning regimen.

Published
2022
Full Text
View/download PDF

11. Additional file 8 of Immunogenicity of personalized dendritic-cell therapy in HIV-1 infected individuals under suppressive antiretroviral treatment: interim analysis from a phase II clinical trial

Author

de Almeida Baptista, Marcella Vass��o, da Silva, La��s Teodoro, Samer, Sadia, Oshiro, Telma Miyuki, Shytaj, Iart Luca, Giron, Leila B., Pena, Nathalia Mantovani, Cruz, Nicolly, Gosuen, Gisele Cristina, Ferreira, Paulo Roberto Abr��o, Cunha-Neto, Ed��cio, Galinskas, Juliana, Dias, Danilo, Sucupira, Maria Cecilia Araripe, de Almeida-Neto, Cesar, Salom��o, Reinaldo, da Silva Duarte, Alberto Jos��, Janini, Lu��s M��rio, Hunter, James R., Savarino, Andrea, Juliano, Maria Aparecida, and Diaz, Ricardo Sobhie

Abstract

Additional file 8: Fig. S8. Inter-group comparison of the immunogenicity of MDDCT. Comparison of the levels of IFN-��, IL-2, and TNF production levels by CD4+ and CD8+ T-cells in individuals receiving MDDCT only (G5) and individuals receiving MDDCT with nicotinamide and auranofin (G6). Data were analyzed by one-way ANOVA followed by Dunn��s post-test. *p

Published
2022
Full Text
View/download PDF

13. Structured Intermittent Therapy with Seven-Day Cycles of HAART for Chronic HIV Infection: A Pilot Study in São Paulo, Brazil.

Author

Casseb, Jorge and Da Silva Duarte, Alberto Jos

Subjects
*ANTIRETROVIRAL agents, *ANTIVIRAL agents, *HIV infections, *HIV-positive persons, *AIDS patients, *DRUG side effects
Abstract

In the last 6 years, an impressive impact of the highly active antiretroviral therapy (HAART) on survival and morbidity in HIV-1–infected individuals has been attained. However, their prolonged use may induce metabolic adverse effects such as lipodistrophy, hypertension, diabetes mellitus, osteopenia and hyperlipidemia. Recently, new strategies such as short-cycle structured intermittent therapy (SIT; 7 days without therapy followed by 7 days with HAART) have been suggested. We tested this strategy in seven (four women and three men; mean of age 39 of years) HIV-positive individuals, all of whom had CD4+ T cell counts greater than 500 cells/mm3 and undetectable plasma viral load for at least 2 years. Our results indicated no opportunistic diseases or CD4 cell count decrease over a mean follow-up of 26 months. No plasma viral replication was detected in five of seven cases. There was a decrease in triglyceride levels to normal range (not statistically significant), but no modification of cholesterol levels. Thus, we recommend a larger clinical trial to determine if SIT is cost effective in developing countries. [ABSTRACT FROM AUTHOR]

Published
2005
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results